DGX Quest Diagnostics Incorporated Common Stock
$245.07
가격 · 8월 24, 2026
기준 재무 정보 7월 23, 2026
52주 범위
$171–$246
99% of range
애널리스트 평점
HOLD
23 analysts
목표 주가
$246
+0% upside
P/E (TTM)
28.3
ROE
14.2%
순이익률
9.0%
Quest Diagnostics Incorporated Common Stock 정보 위키백과 회사 개요
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
더 보기
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
DGX 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$245.07
시가총액
$27.20B
P/E (TTM)
28.3
EPS (TTM)
$8.75
매출 (TTM)
$11.04B
배당 수익률
1.3%
ROE
14.2%
부채/자본
0.8
52주 범위
$171 – $246
DGX 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$11.04B
2016-12-31
→
2025-12-31
EPS
$8.75
2016-12-31
→
2025-12-31
잉여현금흐름
$1.36B
2016-12-31
→
2025-12-31
마진
9.0%
2016-12-31
→
2020-12-31
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
DGX
동종업계 중앙값
P/E (TTM)
28.3
26.5
P/S (TTM)
2.5
2.0
P/B
3.8
4.9
EV / EBITDA
15.3
—
Price / FCF (주가 / FCF)
20.0
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
DGX
동종업계 중앙값
Operating Margin (영업이익률)
14.1%
—
Net Profit Margin (순이익률)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
DGX
동종업계 중앙값
Debt / Equity (부채 / 자기자본 비율)
0.8
—
Current Ratio (유동비율)
1.0
1.6
Quick Ratio (당좌 비율)
0.8
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
DGX
동종업계 중앙값
Revenue YoY (매출 YoY)
11.8%
—
Revenue CAGR 3Y (매출 CAGR 3년)
3.7%
—
Revenue CAGR 5Y (매출 CAGR 5년)
3.2%
—
EPS YoY
13.8%
—
Net Income YoY (순이익 YoY)
13.9%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
DGX
동종업계 중앙값
Payout Ratio (지급 비율)
35.6%
—
배당금 배당 수익률, 지급 비율, 배당 이력, 5년 CAGR
배당 수익률
1.3%
지급 비율
35.6%
5년 배당 CAGR
—
| 배당락일 | 금액 |
|---|---|
| 2026년 7월 8일 | $0.8600 |
| 2026년 4월 6일 | $0.8600 |
| 2026년 1월 13일 | $0.8000 |
| 2025년 10월 3일 | $0.8000 |
| 2025년 7월 7일 | $0.8000 |
| 2025년 4월 7일 | $0.8000 |
| 2025년 1월 14일 | $0.7500 |
| 2024년 10월 4일 | $0.7500 |
| 2024년 7월 8일 | $0.7500 |
| 2024년 4월 5일 | $0.7500 |
| 2024년 1월 16일 | $0.7100 |
| 2023년 10월 5일 | $0.7100 |
| 2023년 7월 10일 | $0.7100 |
| 2023년 4월 6일 | $0.7100 |
| 2023년 1월 17일 | $0.6600 |
| 2022년 10월 3일 | $0.6600 |
| 2022년 7월 5일 | $0.6600 |
| 2022년 4월 5일 | $0.6600 |
| 2022년 1월 18일 | $0.6200 |
| 2021년 10월 4일 | $0.6200 |
DGX 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
23 명의 애널리스트
- 적극 매수 6 26.1%
- 매수 7 30.4%
- 보유 10 43.5%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
15 명의 애널리스트 · 2026-08-23
중앙값
$250.00
지금
$245.07
저가
$204.00
고가
$265.00
중앙값 목표
$250.00
+2.0%
평균 목표
$245.87
+0.3%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
0.09%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $3.12 | $2.85 | 0.27% |
| 2026년 3월 31일 | $2.50 | $2.37 | 0.13% |
| 2025년 12월 31일 | $2.42 | $2.38 | 0.04% |
| 2025년 9월 30일 | $2.60 | $2.53 | 0.07% |
| 2025년 6월 30일 | $2.62 | $2.60 | 0.02% |
| 2025년 3월 31일 | $2.21 | $2.17 | 0.04% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
대차대조표 27
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
현금 흐름 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
수익성 8
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
유동성 및 지급능력 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
성장률 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
손익계산서 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
대차대조표 26
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
현금 흐름 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
유동성 및 지급능력 5
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
효율성 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
가치 평가 (TTM) 14
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| 영업이익률 % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| 순이익 | $992M | $871M | $854M | $946M | $2.00B |
| 희석 EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| 유동비율 | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| 당좌 비율 | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $1.36B | $909M | $864M | $1.31B | $1.83B |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 1,176개의 제출자 · $12.9B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 115 (-25 이전 분기 대비) | 64 (-17 이전 분기 대비) | 415 (+69 이전 분기 대비) | 333 (-20 이전 분기 대비) | +7.5M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1,533,117,858 | 7,233,394 | 11.93% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,299,474,988 | 6,131,045 | 10.11% | 주식 |
| STATE STREET CORP | $1,169,252,484 | 5,516,643 | 9.10% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $584,135,885 | 2,767,754 | 4.54% | 주식 |
| EdgePoint Investment Group Inc. | $476,372,038 | 2,247,568 | 3.71% | 주식 |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400,206,122 | 1,888,207 | 3.11% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $357,050,202 | 1,684,597 | 2.78% | 주식 |
| Davis Selected Advisers | $329,781,509 | 1,555,612 | 2.57% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $311,037,928 | 1,467,506 | 2.42% | 주식 |
| NORGES BANK | $298,133,109 | 1,406,620 | 2.32% | 주식 |
| FMR LLC | $227,315,614 | 1,072,496 | 1.77% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $173,422,135 | 818,220 | 1.35% | 주식 |
| M&G PLC | $168,677,800 | 795,650 | 1.31% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $131,756,386 | 621,639 | 1.03% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $122,662,706 | 625,894 | 0.95% | 주식 |
| AMERIPRISE FINANCIAL INC | $109,652,758 | 517,352 | 0.85% | 주식 |
| Woodline Partners LP | $102,974,000 | 485,841 | 0.80% | 주식 |
| FIDUCIARY MANAGEMENT INC /WI/ | $102,489,906 | 483,557 | 0.80% | 주식 |
| Artemis Investment Management LLP | $99,175,856 | 467,921 | 0.77% | 주식 |
| CRAWFORD INVESTMENT COUNSEL INC | $97,514,204 | 460,081 | 0.76% | 주식 |
| PRINCIPAL FINANCIAL GROUP INC | $91,995,201 | 434,042 | 0.72% | 주식 |
| ENVESTNET ASSET MANAGEMENT INC | $90,834,224 | 428,564 | 0.71% | 주식 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86,608,697 | 407,302 | 0.67% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $83,772,178 | 395,245 | 0.65% | 주식 |
| M.D. Sass, LLC | $76,397,960 | 360,453 | 0.59% | 주식 |
| Qube Research & Technologies Ltd | $72,783,206 | 343,398 | 0.57% | 주식 |
| MACKENZIE FINANCIAL CORP | $70,641,875 | 333,295 | 0.55% | 주식 |
| Advisors Capital Management, LLC | $69,429,626 | 327,575 | 0.54% | 주식 |
| Swiss National Bank | $65,683,305 | 309,900 | 0.51% | 주식 |
| Balyasny Asset Management L.P. | $58,364,883 | 275,371 | 0.45% | 주식 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56,877,630 | 268,354 | 0.44% | 주식 |
| RHUMBLINE ADVISERS | $56,744,612 | 267,727 | 0.44% | 주식 |
| BlackRock, Inc. | $55,976,419 | 264,102 | 0.44% | 주식 |
| Sumitomo Mitsui Trust Group, Inc. | $54,809,634 | 258,597 | 0.43% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $53,654,295 | 253,146 | 0.42% | 주식 |
| Quantinno Capital Management LP | $53,607,358 | 252,924 | 0.42% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $53,249,860 | 251,238 | 0.41% | 주식 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52,211,551 | 246,339 | 0.41% | 주식 |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51,484,139 | 242,907 | 0.40% | 주식 |
| Clark Capital Management Group, Inc. | $51,259,362 | 241,846 | 0.40% | 주식 |
| Vanguard Global Advisers, LLC | $51,025,267 | 240,742 | 0.40% | 주식 |
| Legal & General Group Plc | $50,185,731 | 236,781 | 0.39% | 주식 |
| FIL Ltd | $49,419,958 | 233,168 | 0.38% | 주식 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49,341,000 | 232,797 | 0.38% | 주식 |
| Eurizon Capital SGR S.p.A. | $47,173,414 | 222,564 | 0.37% | 주식 |
| BARCLAYS PLC | $45,003,978 | 212,333 | 0.35% | 주식 |
| PFA Pension, Forsikringsaktieselskab | $43,579,660 | 205,613 | 0.34% | 주식 |
| Integral Health Asset Management, LLC | $42,390,000 | 200,000 | 0.33% | 주식 |
| California Public Employees Retirement System | $41,574,204 | 196,151 | 0.32% | 주식 |
| CONNING INC. | $39,578,271 | 186,734 | 0.31% | 주식 |
| SEB Asset Management AB | $38,766,863 | 182,906 | 0.30% | 주식 |
| BANK OF MONTREAL /CAN/ | $38,512,587 | 181,706 | 0.30% | 주식 |
| GOLDMAN SACHS GROUP INC | $38,322,295 | 180,808 | 0.30% | 주식 |
| Boston Partners | $35,509,632 | 167,514 | 0.28% | 주식 |
| Focus Partners Wealth | $34,616,947 | 163,327 | 0.27% | 주식 |
| STOREBRAND ASSET MANAGEMENT AS | $34,117,592 | 160,970 | 0.27% | 주식 |
| COOKSON PEIRCE & CO INC | $32,977,089 | 155,589 | 0.26% | 주식 |
| UBS Group AG | $32,934,699 | 155,389 | 0.26% | 주식 |
| BRAUN STACEY ASSOCIATES INC | $32,724,232 | 154,396 | 0.25% | 주식 |
| Willis Investment Counsel | $32,110,425 | 151,500 | 0.25% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31,795,403 | 162,238 | 0.25% | 주식 |
| LPL Financial LLC | $30,325,576 | 143,079 | 0.24% | 주식 |
| APG Asset Management N.V. | $27,869,580 | 150,334 | 0.22% | 주식 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26,893,912 | 126,888 | 0.21% | 주식 |
| &PARTNERS | $26,382,365 | 124,363 | 0.21% | 주식 |
| JANE STREET GROUP, LLC | $25,942,680 | 122,400 | 0.20% | 콜 옵션 |
| BANK OF AMERICA CORP /DE/ | $25,492,499 | 120,276 | 0.20% | 주식 |
| Candriam S.C.A. | $25,459,925 | 120,238 | 0.20% | 주식 |
| Squarepoint Ops LLC | $24,974,280 | 117,831 | 0.19% | 주식 |
| Gotham Asset Management, LLC | $24,911,119 | 117,533 | 0.19% | 주식 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24,607,896 | 116,373 | 0.19% | 주식 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24,569,456 | 115,921 | 0.19% | 주식 |
| Robeco Institutional Asset Management B.V. | $23,854,123 | 112,546 | 0.19% | 주식 |
| AEGON ASSET MANAGEMENT UK Plc | $22,866,862 | 107,888 | 0.18% | 주식 |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22,670,926 | 106,964 | 0.18% | 주식 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22,530,921 | 106,303 | 0.18% | 주식 |
| MERCER GLOBAL ADVISORS INC /ADV | $22,106,507 | 104,301 | 0.17% | 주식 |
| Moran Wealth Management, LLC | $22,053,609 | 104,051 | 0.17% | 주식 |
| ABN AMRO Bank N.V. | $21,523,733 | 101,667 | 0.17% | 주식 |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21,496,202 | 123,876 | 0.17% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21,322,170 | 100,600 | 0.17% | 콜 옵션 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21,146,252 | 99,770 | 0.16% | 주식 |
| AVIVA PLC | $20,378,569 | 96,148 | 0.16% | 주식 |
| SCHWARTZ INVESTMENT COUNSEL INC | $20,326,005 | 95,900 | 0.16% | 주식 |
| Boston Common Asset Management, LLC | $20,282,767 | 95,696 | 0.16% | 주식 |
| CAPTRUST FINANCIAL ADVISORS | $20,146,790 | 95,054 | 0.16% | 주식 |
| Midwest Trust Co | $20,113,207 | 94,896 | 0.16% | 주식 |
| LAZARD ASSET MANAGEMENT LLC | $20,035,210 | 94,528 | 0.16% | 주식 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19,842,759 | 93,620 | 0.15% | 주식 |
| BLAIR WILLIAM & CO/IL | $19,773,115 | 93,291 | 0.15% | 주식 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19,613,005 | 92,536 | 0.15% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19,160,280 | 90,400 | 0.15% | 풋 옵션 |
| CITADEL ADVISORS LLC | $18,821,160 | 88,800 | 0.15% | 콜 옵션 |
| WELLINGTON MANAGEMENT GROUP LLP | $17,507,282 | 82,601 | 0.14% | 주식 |
| Foundry Partners, LLC | $17,338,432 | 102,473 | 0.13% | 주식 |
| MARSHALL WACE, LLP | $17,187,874 | 81,094 | 0.13% | 주식 |
| Coho Partners, Ltd. | $16,981,317 | 89,103 | 0.13% | 주식 |
| Copeland Capital Management, LLC | $16,902,800 | 79,749 | 0.13% | 주식 |
| CIBC Asset Management Inc | $16,674,318 | 78,671 | 0.13% | 주식 |
| Mitsubishi UFJ Trust & Banking Corp | $16,558,594 | 78,125 | 0.13% | 주식 |
회사 내부자 53 명의 내부자 · 26 임원 · 26 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 2026년 6월 1일 S | 132,423 | 0 | 5 | $-14,656,302 |
| Surya N Mohapatra | Chairman, President & CEO | 2012년 4월 30일 F | 243,713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 2026년 7월 22일 A | 33,478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 2022년 3월 7일 F | 98,981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 2013년 3월 5일 F | 126,722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 2026년 7월 28일 S | 10,335 | 0 | 1 | $-376,288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026년 7월 22일 L | 13,557 | 0 | 2 | $-2,167,772 |
| Patrick Plewman | SVP for Diagnostic Services | 2026년 7월 22일 L | 15,293 | 0 | 5 | $-2,390,549 |
| Catherine T. Doherty | EVP, Regional Businesses | 2026년 3월 5일 S | 67,122 | 0 | 7 | $-6,671,228 |
| Michael E Prevoznik | SVP & General Counsel | 2026년 3월 5일 S | 37,557 | 0 | 7 | $-6,505,199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 2026년 3월 4일 F | 35,196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 2024년 9월 24일 F | 4,673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 2022년 3월 7일 F | 48,391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 2021년 2월 17일 A | 29,045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 2019년 3월 1일 F | 6,261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 2018년 3월 8일 M | 31,757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 2018년 3월 1일 G | 37,760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2015년 3월 2일 F | 11,837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 2014년 2월 13일 A | 19,890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 2013년 3월 31일 F | 9,569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 2012년 2월 29일 F | 89,232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 2011년 6월 16일 M | 47,150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 2007년 2월 12일 A | 12,974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 2007년 2월 12일 A | 31,079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 2007년 2월 12일 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 2004년 2월 28일 F | 49,609 | 0 | 0 | $0 |
| Wright Lassiter III | 이사 | 2026년 7월 22일 L | 10,323 | 0 | 0 | $0 |
| Vicky B Gregg | 이사 | 2026년 7월 22일 A | 18,386 | 0 | 1 | $-239,700 |
| Robert B Carter | 이사 | 2026년 7월 22일 L | 3,864 | 0 | 0 | $0 |
| Timothy L Main | 이사 | 2026년 7월 22일 L | 22,460 | 0 | 0 | $0 |
| Timothy C Wentworth | 이사 | 2026년 7월 1일 A | 1,358 | 0 | 0 | $0 |
| Timothy M Ring | 이사 | 2026년 5월 20일 A | 31,140 | 0 | 0 | $0 |
| Gary M Pfeiffer | 이사 | 2026년 5월 20일 A | 31,005 | 0 | 1 | $-270,317 |
| Luis Diaz | 이사 | 2025년 5월 15일 A | 4,054 | 0 | 0 | $0 |
| Tracey Doi | 이사 | 2025년 5월 15일 A | 6,490 | 0 | 0 | $0 |
| Gail R Wilensky | 이사 | 2023년 5월 17일 A | 20,506 | 0 | 0 | $0 |
| Stephen H Rusckowski | 이사 | 2023년 3월 6일 F | 389,597 | 0 | 0 | $0 |
| Helen Torley | 이사 | 2021년 5월 25일 A | 6,260 | 0 | 0 | $0 |
| Daniel Stanzione | 이사 | 2020년 11월 23일 S | 28,349 | 0 | 0 | $0 |
| Jenne K Britell | 이사 | 2018년 6월 4일 G | 14,479 | 0 | 0 | $0 |
| Jeffrey M Leiden | 이사 | 2018년 5월 29일 S | 6,000 | 0 | 0 | $0 |
| John B Ziegler | 이사 | 2017년 2월 22일 S | 16,557 | 0 | 0 | $0 |
| John C Baldwin MD | 이사 | 2015년 8월 12일 S | 12,949 | 0 | 0 | $0 |
| William F Buehler | 이사 | 2014년 2월 12일 M | 26,225 | 0 | 0 | $0 |
| GSK plc | 이사 | 2011년 1월 31일 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | 이사 | 2010년 5월 6일 A | 9,334 | 0 | 0 | $0 |
| William R Grant | 이사 | 2007년 4월 1일 A | 3,334 | 0 | 0 | $0 |
| James F Flaherty III | 이사 | 2006년 5월 4일 A | 1,667 | 0 | 0 | $0 |
| Kenneth D Brody | 이사 | 2004년 4월 28일 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | 이사 | 2004년 4월 1일 A | 2,627 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 13 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 2011년 5월 18일 | — | 최초 제출 | M&A / 매각 | SEC |
| 미공개 보고자 | 2011년 2월 1일 | — | 최초 제출 | 수동적 투자 | SEC |
| 미공개 보고자 | 2009년 3월 20일 | — | 최초 제출 | — | SEC |
| GlaxoSmithKline plc ×2 제출 서류 | 2008년 9월 18일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2007년 2월 16일 | — | 최초 제출 | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 제출 서류 | 2006년 1월 19일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2004년 12월 15일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2004년 6월 29일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2002년 6월 24일 | — | 최초 제출 | M&A / 매각 | SEC |
| 미공개 보고자 | 2002년 5월 22일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2002년 4월 12일 | — | 최초 제출 | M&A / 매각 | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 제출 서류 | 2001년 11월 1일 | — | 최초 제출 | M&A / 매각 | SEC |
| 미공개 보고자 | 2001년 5월 14일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 194 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| IHF · iShares Trust | 3.93% | 199,039 SH | 2026년 8월 21일 | 일간 |
| FTDS · First Trust Exchange-Traded Fund | 2.17% | 3,760 NS | 2026년 6월 30일 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.71% | 58,159 SH | 2026년 8월 21일 | 일간 |
| GK · AdvisorShares Trust | 1.43% | 2,156 NS | 2026년 6월 30일 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.29% | 57,932 NS | 2026년 4월 30일 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1.24% | 9,488 SH | 2026년 8월 21일 | 일간 |
| TMFX · RBB Fund, Inc. | 1.05% | 1,724 NS | 2026년 5월 31일 | N-PORT |
| ANEW · ProShares Trust | 0.92% | 364 NS | 2026년 5월 31일 | N-PORT |
| QLTY · GMO ETF Trust | 0.85% | 196,208 NS | 2026년 5월 31일 | N-PORT |
| ALTL · Pacer Funds Trust | 0.82% | 4,047 NS | 2026년 4월 30일 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.80% | 635 NS | 2026년 4월 30일 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.78% | 4,426 SH | 2026년 8월 21일 | 일간 |
| QLV · FlexShares Trust | 0.74% | 6,461 NS | 2026년 4월 30일 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0.72% | 741 NS | 2026년 5월 31일 | N-PORT |
| ESMV · iShares Trust | 0.72% | 236 SH | 2026년 8월 21일 | 일간 |
| PAPI · Morgan Stanley ETF Trust | 0.56% | 10,542 NS | 2026년 6월 30일 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0.52% | 1,956 NS | 2026년 4월 30일 | N-PORT |
| PRAY · FIS Trust | 0.47% | 1,958 NS | 2026년 5월 31일 | N-PORT |
| ITAN · EA Series Trust | 0.46% | 2,110 NS | 2026년 5월 29일 | N-PORT |
| BTAL · AGF Investments Trust | 0.46% | 6,072 NS | 2026년 6월 30일 | N-PORT |
| KNGZ · First Trust Exchange-Traded Fund VI | 0.44% | 1,301 NS | 2026년 6월 30일 | N-PORT |
| QQWZ · Pacer Funds Trust | 0.44% | 1,055 NS | 2026년 4월 30일 | N-PORT |
| COWZ · Pacer Funds Trust | 0.44% | 409,814 NS | 2026년 4월 30일 | N-PORT |
| FVD · First Trust Exchange-Traded Fund | 0.43% | 161,912 NS | 2026년 6월 30일 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0.41% | 3,999 NS | 2026년 5월 31일 | N-PORT |
| IYH · iShares Trust | 0.41% | 65,931 SH | 2026년 8월 21일 | 일간 |
| VOE · VANGUARD INDEX FUNDS | 0.40% | 711,079 SH | 2026년 8월 19일 | 일간 |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.38% | 8,682 NS | 2026년 4월 30일 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.37% | 8,368 NS | 2026년 4월 30일 | N-PORT |
| IMCV · iShares Trust | 0.37% | 18,030 SH | 2026년 8월 21일 | 일간 |
| SUSA · iShares Trust | 0.35% | 59,963 SH | 2026년 8월 21일 | 일간 |
| FHLC · FIDELITY COVINGTON TRUST | 0.35% | 51,278 NS | 2026년 4월 30일 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0.34% | 23,030 NS | 2026년 4월 30일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.34% | 330,273 SH | 2026년 8월 19일 | 일간 |
| IXJ · iShares Trust | 0.32% | 58,047 SH | 2026년 8월 21일 | 일간 |
| RXL · ProShares Trust | 0.31% | 1,147 NS | 2026년 5월 31일 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.31% | 2,194 NS | 2026년 4월 30일 | N-PORT |
| GNOM · Global X Funds | 0.28% | 789 NS | 2026년 5월 31일 | N-PORT |
| DFLV · Dimensional ETF Trust | 0.26% | 79,983 NS | 2026년 4월 30일 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.26% | 7,703,000 | 2026년 8월 19일 | 일간 |
| IWS · iShares Trust | 0.25% | 166,379 SH | 2026년 8월 21일 | 일간 |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.24% | 18,806 NS | 2026년 4월 30일 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0.24% | 8,995 NS | 2026년 4월 30일 | N-PORT |
| EQIN · Columbia ETF Trust I | 0.23% | 3,340 NS | 2026년 4월 30일 | N-PORT |
| CVMC · Morgan Stanley ETF Trust | 0.23% | 1,137 NS | 2026년 6월 30일 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.23% | 26,229 NS | 2026년 4월 30일 | N-PORT |
| SIZE · iShares Trust | 0.23% | 4,242 SH | 2026년 8월 21일 | 일간 |
| DFVE · DoubleLine ETF Trust | 0.23% | 351 NS | 2026년 6월 30일 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0.23% | 2,398,948 SH | 2026년 8월 19일 | 일간 |
| EUSA · iShares, Inc. | 0.22% | 18,045 SH | 2026년 8월 21일 | 일간 |